HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

der to reduce the incidence and severity of infusion-related adverse events. Patients also received prophylactic anti-infective treatment to reduce the risk of opportunistic infections. The primary endpoint for this trial was overall response rate (complete and partial response), and the study objective was to demonstrate a major response rate of at least 20 percent. Response rate was assessed by an independent review panel in accordance with the National Cancer Institute's guidelines for the diagnosis and treatment of CLL.

Of 93 evaluable patients, 31 demonstrated an objective response to treatment, for an overall response rate of 33%. Two of these responses were complete (2%) and 29 were partial responses (31%). Another 55 (59%) patients had disease stabilization. Median survival time has not yet been reached at about 10 months after the last patient was enrolled.

The safety profile of CAMPATH was consistent with that seen in previous studies and was judged by the investigators to be acceptable in this group of endstage CLL patients.

Adverse effects associated with CAMPATH in this study of 93 patients were mostly mild to moderate infusion-related symptoms. Severe (grade 3 and 4) infusion-related symptoms included: fever (13%), rigors (11%), dyspnea (6%), and hypotension (1%). During the study patients developed severe (grade 3 and 4) thrombocytopenia (low platelet count, 51%) or neutropenia (low white blood cell count, 61%) that usually improved within two months post-therapy. Some patients entering the study with severe (grade 3 and 4) thrombocytopenia and neutropenia improved to grade 2 or better within two months post-therapy: thrombocytopenia -- 7 of 19 (37%) patients improved,neutropenia -- 11 of 17 (65%) patients improved.

No unexpected serious adverse events were reported. The incidence of serious infections was reported to be 20% on this trial. It should be noted that infection is a common complication and cause of death
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... was diagnosed with Ebola while working for NBC News ... leave the special isolation unit at Nebraska Medical Center in Omaha, ... hospital said Tuesday. A blood test confirmed by the U.S. ... can head home to Providence, R.I., NBC News reported ...
(Date:10/20/2014)... PA (PRWEB) October 20, 2014 Allegheny ... minimally-invasive procedure that enables physicians to repair a damaged ... The MitraClip system, developed by Abbott ... (MR), a progressive and life-threatening condition in which the ... blood to flow backward from the heart’s left ventricle ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, ... Columbus, Inc., A Division of MaternOhio Clinical Associates, Inc., ... 100,000 patients annually. Dr. Murphy will provide a full ... a women’s life. She is accepting new patients at ... Dublin. , Dr. Murphy offers a wide variety of ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
(Date:10/22/2014)... 2014   Surefire Medical , Inc., the developer ... maximize targeted delivery of embolization agents in minimally invasive ... John R. Daniels , MD of the University ... oncologist Steven C. Katz , MD of the ... Advisory Board (SAB).    "The role of ...
(Date:10/22/2014)... Oct. 22, 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: ... its novel investigational drug for cancer, is designed for ... side effects. Its oncology focus is on melanoma, breast ... phase 2 trials of PV-10 as a therapy for ... for atopic dermatitis and psoriasis. This ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014  PneumRx, Inc. ... interventional pulmonology, today announced completion of enrollment in their ... RENEW Clinical Study is the FDA-approved IDE pivotal trial ... severe emphysema. It was anticipated that the ... February 2013, would take until the end of 2014 ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
Cached News: